Recent Updates
Recently added Catalysts
OMER Neutral Sentiment

Omeros Corporation to Announce Third Quarter Financial Results on November 16, 2026

Tuesday, November 10, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Omeros Corporation will release its third quarter financial results on November 16, 2026, after market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and recent developments. This event is part of their regular financial reporting schedule.

Market Sentiment Analysis

POSITIVE FACTORS

  • Omeros will announce Q3 financial results.
  • Management will discuss recent developments.
  • Conference call scheduled for November 16.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+411%
120-day peak, hindsight
Typical move
22%
average across 6 past catalysts
Lead asset
OMS906
Phase 2 · Paroxysmal Nocturnal Hemoglobinuria

Full Press Release Details

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the third quarter of 2026 on Monday, November 16, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss recent developments and highlights as well as the Company’s financial results. Conference Call Details and Webcast Link Instructions To access the live webcast, please c

Frequently Asked Questions

When will Omeros announce its Q3 financial results?

Omeros will announce its Q3 financial results on November 16, 2026.

What time is the Omeros conference call?

The conference call is scheduled for 4:30 p.m. Eastern Time.

How can I access the Omeros webcast?

Details for accessing the live webcast will be provided in the announcement.

What will Omeros discuss during the call?

Omeros will discuss recent developments and financial results.

ShareAdd on Google
Tags: OMER Omeros financial results Q3 2026 conference call NASDAQ: OMER
Last updated: Nov 10, 2026

Biotech snapshot

Cash runway
$132M liquidity · $0M/mo burn
Low dilution risk
Lead asset
OMS906Phase 2
Paroxysmal Nocturnal Hemoglobinuria →

Catalyst track record

+411%
best trade around OMER's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for OMER.

See every catalyst's timing & PoA →